News Releases

Printer friendly version

Protox Appoints Dr. Samuel Denmeade as Chief Scientific Officer

Vancouver, British Columbia, October 22, 2007 – Protox Therapeutics Inc. (TSX-V:PRX) today announced that it has appointed Dr. Samuel Denmeade to the position of Chief Scientific Officer, effective immediately.

“Dr. Denmeade’s wealth of experience as a physician and scientist with an active clinical practice is a significant addition to the Protox team,” said Dr. Fahar Merchant, President and CEO of Protox. “As we move towards the initiation of our Phase 2 trials for localized prostate cancer and BPH, Dr. Denmeade’s significant expertise as an investigator in several clinical trials, as well as his substantial research in the development of PRX302 and other targeted therapies for the treatment of cancer will be invaluable to Protox.”

Dr. Samuel Denmeade is co-inventor of PRX302, Protox’s lead candidate for the treatment of prostate cancer and BPH. He is Associate Professor at Johns Hopkins University School of Medicine and also a member of the Chemical Therapeutics Program within the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He has an active clinical practice in genitourinary oncology and has been the principal investigator in several clinical trials in addition to being a co-investigator in a large number of trials conducted by the Genitourinary Oncology Clinical Group at Johns Hopkins. Dr Denmeade has published over 50 papers based on his laboratory research most of them focused in the development of targeted therapies for prostate cancer. Dr. Denmeade has been the recipient of several research awards including those from the NIH, the Department of Defense, the Prostate Cancer Foundation and the Susan Komen Breast Cancer Research Foundation. He graduated magna cum laude with a degree in Biochemistry from Columbia University and earned his MD at Columbia University College of Physicians and Surgeons. He received his residency training at the University of Chicago before his fellowship training in medical oncology at Johns Hopkins. Dr Denmeade is a member of the Editorial Board of the journal, The Prostate.

“We are very appreciative of Dr. Tom Buckley’s efforts and contribution in the successful development of Protox’s pipeline,” said Dr. Merchant. “While Dr. Buckley is retiring from active laboratory research, we are pleased that he will continue to play an important role as our scientific advisor and consultant guiding the future growth of the PORxin platform.”

About Protox
Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Two novel drug candidates derived from the company’s INxin™ and PORxin™ platforms are being developed in three clinical programs.  A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. Phase 1 clinical trials evaluating PRX302 (PORxin) have been completed for the treatment of localized prostate cancer and benign prostatic hyperplasia (enlarged prostate).

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

James Beesley
Director, Investor Relations
Protox Therapeutics
604-688-0199
jbeesley@protoxtherapeutics.com

Michael Moore
Investor Relations
The Equicom Group
416-815-0700 x 241
mmoore@equicomgroup.com